Evidence-Based Reviews

Risks of increasingly potent Cannabis: The joint effects of potency and frequency

Current Psychiatry. 2017 February;16(2):14-20

As THC levels rise, the risk of psychosis, cognitive deficits, and structural brain changes increases

References

1. Mehmedic Z, Chandra S, Slade D, et al. Potency trends of ∆9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci. 2010;55(5):1209-1217.
2. ElSohly MA, Mehmedic Z, Foster S, et al. Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol Psychiatry. 2016;79(7):613-619.
3. Sevigny EL. Is today’s marijuana more potent simply because it’s fresher? Drug Test Anal. 2012;5(1):62-67.
4. Pierre JM, Gandal M, Son M. Cannabis-induced psychosis associated with high-potency “wax dabs.” Schizophr Res. 2016;172(1-3):211-212.
5. Vandrey R, Raber JC, Raber ME, et al. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 2015;313(24):2491-2493.
6. Friese B, Slater MD, Annechino R, et al. Teen use of marijuana edibles: a focus group study of an emerging issue. J Prim Prev. 2016;37(3):303-309.
7. Lamy FR, Daniulaityte R, Sheth A, et al. “Those edibles hit hard”: exploration of Twitter data on cannabis edibles in the U.S. Drug Alcohol Depend. 2016;164:64-70.
8. Hancock-Allen JB, Barker L, VanDyke M, et al. Death following ingestion of an edible marijuana product—Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771-772.
9. MacCoun RJ, Mellow MM. Half-baked—The retail promotion of marijuana edibles. N Engl J Med. 2015;372(11):989-990.
10. Stogner JM, Miller BL. Assessing the dangers of “dabbing”: mere marijuana or harmful new trend? Pediatrics. 2015;136(1):1-3.
11. Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? Addict Behav. 2014;39(10):1430-1433.
12. Keller CJ, Chen EC, Bodsky K, et al. A case of butane hash oil (marijuana wax)-induced psychosis. Subst Abus. 2016;37(3):384-386.
13. Jensen G, Bertelotti R, Greenhalgh D, et al. Honey oil burns: a growing problem. J Burn Care Res. 2015;36(2):e34-e37.
14. Campos AC, Fogaça MV, Sonego AB, et al. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119-127.
15. Gururajan A, Malone DT. Does cannabidiol have a role in the treatment of schizophrenia? Schizophr Res. 2016;176(2-3):281-290.
16. Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2103. JAMA Psychiatry. 2015;72(12):1235-1242.
17. Compton WM, Grant BF, Colliver JD, et al. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. 2004;291(17):2114-2121.
18. van der Pol P, Liebregts N, Brunt T, et al. Cross-sectional and prospective relation to cannabis potency, dosing and smoking behavior with cannabis dependence: an ecological study. Addiction. 2014;109(7):1101-1109.
19. Freeman TP, Morgan CJ, Hindocha C, et al. Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction. 2015;109(10):1686-1694.
20. Freeman TP, Winstock AR. Examining the profile of HPC and its association with severity of cannabis dependence. Psychol Med. 2015;45(15):3181-3189.
21. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549-556.
22. Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-1269.
23. Pierre JM. Cannabis, synthetic cannabinoids, and psychosis risk: what the evidence says. Current Psychiatry. 2011;10(9):49-58.
24. Pierre JM. Psychosis associated with medical marijuana: risk vs. benefits of medicinal cannabis use. Am J Psychiatry. 2010;167(5):598-599.
25. Di Forti M, Morgan C, Dazzan P, et al. HPC and the risk of psychosis. Br J Psychiatry. 2009;195(6):488-491.
26. Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry. 2015;2(3):233-238.
27. Di Forti M, Sallis H, Allegri F, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509-1517.
28. Schoeler T, Pestros N, Di Forti M, et al. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry. 2016;3(10):947-953.
29. Cohen PJ. Medical marijuana: the conflict between scientific evidence and political ideology. Part one of two. J Pain Pall Care Pharmacother. 2009;23(1):4-25.
30. Crean RD, Crane NA, Mason BJ. An evidence-based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1-8.
31. Volkow N, Swanson JM, Evins E, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292-297.
32. Hart CL, van Gorp W, Haney M, et al. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25(5):757-765.
33. Vadhan NP, Hart CL, van Gorp WG, et al. Acute effects of smoked marijuana on decision making, as assessed by a modified gambling task, in experienced marijuana users. J Clin Exp Neuropsychol. 2007;29(4):357-364.
34. Ramaekers JG, Kauert G, van Ruitenbeek P, et al. High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology. 2006;31(10):2296-2303.
35. Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420-429.
36. Rocchetti M, Crescini A, Borgwardt S, et al. Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psychiatr Clin Neurosci. 2013;67(7):483-492.
37. Battistella G, Fornari E, Annoni J, et al. Long-term effects of cannabis on brain structure. Neuropsychopharmacology. 2014;39(9):2041-2048.
38. Gilman JM, Kuster JK, Lee S, et al. Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci. 2014;34(16):5529-5538.
39. Becker MP, Collins PF, Lim KO, et al. Longitudinal changes in white matter microstructure after heavy cannabis use. Dev Cog Neurosci. 2015;16:23-35.
40. Rigucci S, Marques TR, Di Forti M, et al. Effect of high potency cannabis on corpus callosum microstructure. Psychol Med. 2016:46(4):841-854.
41. Cavazos-Rehg PA, Sowles SJ, Krauss MJ, et al. A content analysis of tweets about high-potency marijuana. Drug Alcohol Depend. 2016;166:100-108.
42. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA. 2015;313(24):2474-2483.

In the United States, the average potency of Cannabis has increased significantly over the past few decades in response to consumer demand and policies in some states that have legalized marijuana for medicinal and recreational purposes.¹ Whereas the delta-9-tetrahydrocannabinol (THC) content of “street” marijuana was <1% in the 1970s and 4% in the 1990s, by 2012, analyses of Cannabis samples seized by law enforcement agencies documented a rise in average THC potency to >12%.^1-3

Although this increase in potency has been overstated in the media because studies did not control for the effects of changes in sampling methods on freshness, it is estimated that Cannabis potency increased 7-fold from 1970 to 2010.³ Also, Cannabis preparations such as hashish and hash oil extracts containing THC well above average—from 35% to 90% THC—are now more widely available. In states where marijuana has been legalized, high-potency Cannabis (HPC) in the form of “edibles” (eg, marijuana added to baked goods, candy, or drinks) and hash oil extracts (Table 1)^4-13 can be readily obtained from dispensaries or even at local farmers’ markets.

The potency of Cannabis, typically defined as the percentage of THC, its chief psychoactive component, varies depending on the genetic strain of the plant, cultivation techniques, and methods of processing and storage. For example, relative to “average marijuana,” hemp (Cannabis bred for industrial purposes) has very little THC, while sinsemilla (flowering buds from unpollinated female plants), hashish (Cannabis resin), and extracted hash oil contain increasing amounts of THC (Table 2).^1,2

As THC levels in Cannabis have risen over time, cannabidiol (CBD) levels have dropped to <0.2%.² Although THC appears to be largely responsible for the psychiatric morbidity associated with Cannabis, CBD may have neuroprotective and antipsychotic properties.^14,15 The sharp spike in the THC:CBD ratio in recent years therefore raises the possibility that Cannabis use today might carry a much greater risk of psychiatric sequelae than it did in previous generations.

This article reviews the evidence for an increased risk of psychiatric morbidity with increasing Cannabis potency.

Risks of increasingly potent Cannabis: The joint effects of potency and frequency

References

Pages

Recommended Reading